



Personalized Medicine in Autoimmune Diseases

Guest Editor:

Dr. Roberto Díaz Peña

Fundación Publica Galega de
Medicina Xenómica, SERGAS,
Grupo de Medicina Xenómica-
USC, Instituto de Investigación
Sanitaria de Santiago (IDIS),
Santiago de Compostela, Spain

Deadline for manuscript
submissions:

closed (5 August 2021)

Message from the Guest Editor

Dear Colleagues,

The ultimate aim of genomic studies in autoimmunity, and in any human disease, is to understand their pathogenesis in order to identify novel therapeutic approaches. The implementation of -omics techniques will bring considerable progress to our knowledge of disease etiology and manifestations and have a determinant impact on the discovery of new biomarkers suitable for clinical practice.

Genomics is the key component in biomedical research toward personalized medicine. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current state of the utilization or implementation of genomic technologies in autoimmunity. Mainly, we call for papers that are focused on the field of genomics in autoimmune diseases, and their potential to be useful for the diagnosis and treatment of these conditions. We encourage the submission of reviews and original articles which describe a personalized medicine approach to the diagnosis, classification, and treatment approach to autoimmune diseases.

Dr. Roberto Díaz Peña
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)